Lecanemab in Early Alzheimer’s Disease-Reference-Cited by-同舟云学术

Lecanemab in Early Alzheimer’s Disease

Published:2023-01-05 Issue:1 Volume:388 Page:9-21
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

van Dyck Christopher H.¹,Swanson Chad J.¹,Aisen Paul¹,Bateman Randall J.¹,Chen Christopher¹,Gee Michelle¹,Kanekiyo Michio¹,Li David¹,Reyderman Larisa¹,Cohen Sharon¹,Froelich Lutz¹,Katayama Sadao¹,Sabbagh Marwan¹,Vellas Bruno¹,Watson David¹,Dhadda Shobha¹,Irizarry Michael¹,Kramer Lynn D.¹,Iwatsubo Takeshi¹

Affiliation:

1. From the Alzheimer’s Disease Research Unit, Yale School of Medicine, New Haven, CT (C.H.D.); Eisai, Nutley, NJ (C.J.S., M.K., D.L., L.R., S.D., M.I., L.D.K.); the Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego (P.A.); Washington University School of Medicine in St. Louis, St. Louis (R.B.); the Memory, Aging, and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (C.C.); Eisai, Hatfield,...

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2212948

Reference27 articles.

1. Current and evolving treatment strategies for the Alzheimer disease continuum

2. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

3. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

4. The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

5. Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation

Cited by 1899 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dementia and Cognitive Impairment;International Encyclopedia of Public Health;2025

2. Lecanemab Planning;Neurology Clinical Practice;2024-12

3. An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation;Neurology Clinical Practice;2024-12

4. Recent advances in nanoenzymes for Alzheimer's disease treatment;Colloids and Surfaces B: Biointerfaces;2024-12

5. Recent updates on immunotherapy in neurodegenerative diseases;Brain Research;2024-12